Mitral regurgitation (MR) is the backflow of blood from the left ventricle into the left atrium during left ventricular systole. The mitral valve is located in the opening between the left atrium and the left ventricle. It opens to allow blood from the left atrium to fill the left ventricle. When the left ventricle contracts, the mitral valve closes so that pumped blood can only flow into the aorta. When the mitral valve is not fully closed, some blood can leak back into the left atrium. Mitral regurgitation can be divided into primary and secondary MR according to the pathogenesis. Primary mitral regurgitation is due to the pathological changes of one or more of the mitral valve leaflets, valve annulus, chordae tendineae and papillary muscles, such as degenerative disease or rheumatic disease, which cause the mitral valve to fail to close normally. Secondary mitral valve regurgitation is functional mitral valve regurgitation, which is caused by the disease of the heart itself or the valve supporting structure, such as pathological changes of the myocardium leading to pathological dilatation of the left ventricle and mitral valve annulus or Mitral regurgitation due to localized displacement of the left ventricle and subvalvular device. The current quantitative assessment of mitral valve regurgitation, the current standards of various guidelines and documents are not completely consistent, generally divided into mild, moderate and severe, this classification is relatively broad, can not well reflect the changes and manifestations before and after surgery effect of surgery. In the MitraClip system clinical trial, mitral regurgitation was divided into no (0+), mild (1+), moderate (2+), moderate to severe (3+), severe (4+), and then more This classification method is used in several clinical studies of mitral valve regurgitation interventional therapy.
This report contains market size and forecasts of Mitral Regurgitation in Global, including the following market information:
Global Mitral Regurgitation Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Mitral Regurgitation market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Primary Mitral Regurgitation Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Mitral Regurgitation include Edwards Lifesciences, Abbott, CardioSolution, NeoChord, Mitralign, Medtronic, Boston Scientific, Mitralix and Shanghai Hanyu Medical Technology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Mitral Regurgitation companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Mitral Regurgitation Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Mitral Regurgitation Market Segment Percentages, by Type, 2021 (%)
Primary Mitral Regurgitation
Secondary Mitral Regurgitation
Global Mitral Regurgitation Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Mitral Regurgitation Market Segment Percentages, by Application, 2021 (%)
Transapical
Via Stock and Via Interstitial
Right Internal Jugular Vein
Global Mitral Regurgitation Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Mitral Regurgitation Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Mitral Regurgitation revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Mitral Regurgitation revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Edwards Lifesciences
Abbott
CardioSolution
NeoChord
Mitralign
Medtronic
Boston Scientific
Mitralix
Shanghai Hanyu Medical Technology
Valgen Holding Corporation
NeoChord
CoreMedic
Babic Chord
Gore Medical
Valtech Cardio
Transcardiac
ChoRe
AVVIE
Cardiovalve
HighLife SAS
Neovasc
MitrAssist Lifesciences
Shanghai NewMed Medical
Peijia Medical
MicroPort CardioFlow Medtech